bioRASI Joins GPhA Biosimilar Council

MIAMI, Aug. 31, 2016 /PRNewswire/ -- Biorasi, a contract research organization (CRO) that optimizes trial design and delivery for sponsor organizations, is proud to announce that the company is now an associate member organization of the Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA). This newly minted alliance provides Biorasi with the opportunity to work with the world's leading-edge biosimilar developers, helping to influence policies, form best practices, and promote science-based research and findings related to biosimilar drugs. 

Biorasi is a CRO widely recognized for delivering success in complex clinical trials.

"By interacting with Biosimilars Council member organizations, pharmaceutical and biotechnology manufacturers and stakeholders, legislators and regulatory agencies including the U.S. Food and Drug Administration (FDA), our team can have an impact on legislation and regulation around clinical developments to foster the rapid approval of biosimilars," said Stephanie Finnegan, President, Divisional Operations for Biorasi. "We are honored to be included in this esteemed group, and we hope to be able to contribute and add value around the clinical development of these molecules."

"We welcome Biorasi as an associate member to the Biosimilars Council," said Bert Liang, Chair of the Biosimilars Council and CEO of Pfenex, Inc. "Biorasi brings significant experience in clinical research, broadening Council depth and allowing us to connect more deeply with stakeholders across the market in our goal to increase patient access to biosimilars. We look forward to a positive and mutually beneficial relationship with the Biorasi team."

To learn more about the GPhA Biosimilars Council and Biorasi's role as a member organization, read our full article.

About Biorasi
Biorasi is a customer-focused contract research organization (CRO) that optimizes the design and delivery of clinical trials for its sponsors. Pharmaceutical companies around the globe have come to depend on Biorasi to consistently deliver success in clinical-phase development programs. Biorasi's expertise includes a wide range of molecule types, therapeutic areas, and regulatory pathways. Biorasi has collaborated with sponsors to enable FDA, EMA, and multi-venue approvals for numerous small molecules and biologics, and is also a leader in the emerging biosimilars sector.

Established in 2002, Biorasi is an employee-owned company headquartered in Miami, Florida and with office-based teams around the globe. The company has received the coveted CRO Leadership Award from Life Science Leader magazine and has placed on the Inc. 500 list of America's fastest-growing companies. For more information, visit

About GPhA
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 88 percent of the prescriptions dispensed in the U.S. but consume just 28 percent of the total drug spending. Additional information is available at Follow us on twitter: @gpha.

About the GPhA Biosimilars Council
The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at

David Bryant
(786) 388-0700

Logo -

To view the original version on PR Newswire, visit:

SOURCE Biorasi

Back to news